Study of cases of Pseudomonas aeruginosa bacteria in patients with severe COVID-19
Infectious Diseases: News, Opinions, Training
; 11(4):47-55, 2022.
Article
in Russian
| EMBASE | ID: covidwho-2324703
ABSTRACT
Pseudomonas aeruginosa can cause severe nosocomial infections and sepsis, especially in immunocompromised comorbid patients. The purpose of the study was to assess the frequency, clinical course, and the possibility of antimicrobial therapy for bloodstream infections caused by P. aeruginosa in patients with COVID-19. Material and methods. A retrospective single-center uncontrolled study was performed from October 1, 2020 to September 31, 2021 on the basis of a temporary infectious diseases hospital for patients with COVID-19 at the City Clinical Hospital No. 52, Moscow. During the analyzed period, 16 047 patients were admitted to the infectious diseases hospital. The study included 46 patients over 18 years of age with a diagnosis of COVID-19 confirmed by PCR RNA SARS-CoV-2 nasopharyngeal swab (U 07.1) and/or computed tomography (CT) of the lungs (U 07.2). Statistical data processing was carried out using the BioStat, 2009 program (AnalystSoft, USA). Results and discussion. P. aeruginosa has been isolated from the blood of 0.29% of patients with COVID-19. In the structure of bacteremia, P. aeruginosa accounted for 6.1%. In 87% of cases, pathogens were isolated from the blood of patients in the ICU. Most strains are classified as XDR phenotypes - 74% and MDR - 21.7%. The sensitivity of hospital strains of P. aeruginosa was to colistin - 97%, to amikacin - 39.1%, meropenem - 32.6%. All patients had concomitant diseases cardiovascular (60%), oncological (27.5%), diabetes mellitus (20%), obesity (22.5%) and others. In 47.5% of cases (19/40), the cause of bloodstream infections was ventilator-associated pneumonia. The mortality rate among patients with COVID-19 with P. aeruginosa bacteremia is 80%. Conclusion. The wide distribution of multidrug-resistant strains of P. aeruginosa limits the number of therapeutic options. In severe bloodstream infections caused by P. aeruginosa XDR, combined antibiotic therapy regimens with the inclusion of polymyxin B are advisable.Copyright © 2022 Tomsk Polytechnic University, Publishing House. All rights reserved.
antibiotic resistance; bacteremia; bloodstream infections; covid-19; ecmo; icu; Pseudomonas aeruginosa; antibiotic sensitivity; article; bacterium isolate; bloodstream infection; cardiovascular disease; computer assisted tomography; coronavirus disease 2019; diabetes mellitus; disease course; human; human tissue; intensive care unit; major clinical study; malignant neoplasm; nasopharyngeal swab; nonhuman; obesity; phenotype; polymerase chain reaction; priority journal; Pseudomonas infection; retrospective study; Russian Federation; Severe acute respiratory syndrome coronavirus 2; ventilator associated pneumonia; amikacin; colistin; meropenem; virus RNA/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Observational study
/
Prognostic study
Language:
Russian
Journal:
Infectious Diseases: News, Opinions, Training
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS